Synergy suffers from constipation of cash?
Aggiornato
Very good news came for Synergy pharmaceuticals, the FDA approved expanded indication to treat irritable bowel for one of their products.
However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.
I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.
I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
Nota
Nop, not good.Trade chiuso: stop raggiunto
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.